Skip to content

An Oral Doxycycline Regimen to Prevent Bacteremia Following Dental Procedures

An Oral Doxycycline Regimen to Prevent Bacteremia Following Dental Procedures

Status
Not yet recruiting
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06422221
Enrollment
150
Registered
2024-05-20
Start date
2024-07-15
Completion date
2025-06-30
Last updated
2024-06-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bacteremia, Endocarditis

Brief summary

Although controversy exists regarding the efficacy of antibiotic prophylaxis for patients at risk of infective endocarditis, expert committees continue to publish recommendations for antibiotic prophylactic regimens. The last American Heart Association (AHA) and European Society of Cardiology (ESC) guidelines include several important changes, highlighting that clindamycin (CLI) is no longer recommended as an alternative to amoxicillin in those allergic to penicillin. This new project aims to evaluate the effectiveness of oral doxycycline in preventing post-dental extraction bloodstream infection.

Detailed description

PURPOSE: Despite the controversy about the risk of developing bacterial endocarditis of oral origin, numerous Expert Committees in different countries continue to publish prophylactic regimens. To date, the literature is unclear about the role of antimicrobial prophylaxis in the prevention of bacteremia following dental procedures. The aim of this study is to evaluate the efficacy of prophylactic dosage with oral doxycycline (DXC) in the prevention of bacteremia following dental extractions. SELECTION OF THE STUDY GROUP AND STUDY DESIGN: The study group will comprise patients who, for behavioral reasons (autism, learning disabilities, phobias, etc.), will undergo dental extractions under general anesthesia in the Santiago de Compostela University Hospital (Santiago de Compostela, Spain). 150 patients will be selected and will be randomly distributed into 3 study groups: control group (receiving no prophylaxis), CLI group (receiving 600 mg oral CLI) and DXC group (receiving 100 mg oral DXC). COLLECTION OF SAMPLES FOR BLOOD CULTURE: To determine the prevalence of bacteremia, a peripheral venous blood sample (10 ml) will be drawn from each patient. Samples will be inoculated in BACTEC plus (Becton Dickinson and Company, Sparks, MD) aerobic and anaerobic blood culture bottles, and will be processed in the Bactec 9240 (Becton Dickinson). MICROBIOLOGICAL ANALYSIS OF BLOOD CULTURES: A Gram stain will be performed on each positive blood culture. The positive blood cultures in the aerobic media will be subcultured on blood agar and chocolate agar in an atmosphere of 5 to 10% carbon monoxide and on MacConkey agar under aerobic conditions. The same protocol will be used for the positive blood cultures in the anaerobic media, with subculture on Schaedler agar and incubation in an anaerobic atmosphere. The bacteria isolated will be identified by using the battery of biochemical tests provided with the Vitek system for Gram-positive bacteria, Neisseria spp., Haemophilus spp., and obligate anaerobic bacteria. The viridans group streptococci will be classified into five groups, the Streptococcus mitis, S. anginosus, S. salivarius, S. mutans, and S. bovis groups, by applying the Ruoff criteria. Facklam's criteria will be used to identify unusual Streptococcus spp. and other Gram-positive cocci in chains. The subculture and further identification of the isolated bacteria will be performed by conventional microbiological techniques. The collection, handling, and transport of the blood samples for blood culture will be performed according to the recommendations of the Spanish Society of Infectious Diseases and Clinical Microbiology.

Interventions

DRUGClindamycin

Receiving 600 mg oral Clindamycin 1 hour before general anesthesia and before any dental manipulation

DRUGDoxycycline

Receiving 100 mg oral Doxycycline 1 hour before general anesthesia and before any dental manipulation

Sponsors

Hospital Clinico Universitario de Santiago
CollaboratorOTHER
University of Santiago de Compostela
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Subject)

Masking description

Single

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Subjects must have at least 10 teeth. * Subjects must have the need for a dental extraction under general anesthesia (for behavioral reasons). * Subjects will be recruited regardless of the extent and severity of their dental and/or periodontal disease.

Exclusion criteria

* Age under 18 years * Body weight under 40 kg * Receipt of antibiotics in the previous 3 months * Routine use of oral antiseptics * A history of allergy or intolerance to doxycycline * A history of allergy or intolerance to cindamycin * Any type of congenital or acquired immunodeficiency * Any known risk factor for bacterial endocarditis * Any known risk factor for prolonged bleeding

Design outcomes

Primary

MeasureTime frameDescription
Bacteremia in participants receiving a prophylactic dosage with oral doxycyclinChanges from baseline at 30 seconds and 15 minutes after the final dental extractionPositive cultures

Secondary

MeasureTime frameDescription
Bacteremia in participants receiving a prophylactic dosage with oral clindamycinChanges from baseline at 30 seconds and 15 minutes after the final dental extractionPositive cultures
Bacteremia in participants receiving no prophylaxisChanges from baseline at 30 seconds and 15 minutes after the final dental extractionPositive cultures

Countries

Spain

Contacts

Primary ContactJAVIER Feijoo
javier.fernandez@usc.es+34636962202
Backup ContactPedro Diz Dios
pedro.diz@usc.es+34617864293

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026